Consolidated Sales (Cr) Growth EBITDA (Cr) Margin PAT Margin EPS (Rs) P/E RoE

Similar documents
Initiating Coverage. Uflex Ltd.

Margin (%) PAT (Rs cr)

Initiating Coverage. Vaibhav Global Ltd. (VGL) BUY Back On Track Huge Potential Ahead. 1 P a g e

Institutional Equities

Gillette India. Institutional Equities. 2QFY19 Result Update BUY. Marketing Investments Mask Improved Top-line Performance

Jamna Auto Industries

Indian Oil Corporation

Gillette India. Institutional Equities. 1QFY18 Result Update

Colgate-Palmolive (India)

Sanofi India. Institutional Equities. 3QCY18 Result Update. Robust Performance BUY

Power Mech Projects. Institutional Equities. 2QFY19 Result Update BUY. Strong Order Book Drives Robust Execution

Dalmia Bharat Enterprises

ITC. Institutional Equities. 4QFY18 Result Update. Tracking Expectations ACCUMULATE. Sector: FMCG CMP: Rs286 Target Price: Rs290 Upside: 1%

EBITDA 5,076 3, , EBITDA

Phillips Carbon Black Ltd

NESCO. Institutional Equities. Event Update. Revenues From Bombay Exhibition Centre May Take A Hit BUY

Valuation and Outlook. Growth (%) PAT (Rs cr)

Indian Oil Corporation

Phillips Carbon Black Ltd

Institutional Equities

Mold-Tek Packaging. Institutional Equities. Conference Update. Promising Growth Outlook BUY

Punjab National Bank

Recommendation HOLD Results in line with our expectations CMP (15/10/2010) Rs Target Rs Sector

Nestle India. Institutional Equities. 1QCY18 Result Update. Resurgence Continues BUY. Sector: FMCG CMP: Rs8,981 Target Price: Rs10,700 Upside: 19%

South Indian Bank. Institutional Equities. 4QFY18 Result Update. Asset Quality Pain To Ease Hereafter BUY. 15 May 2018

Bata India. Institutional Equities. 1QFY19 Result Update BUY

Initiating Coverage. Dr Lal Path Labs Ltd. 1 P a g e. related healthcare tests and services in India. Dr Lal Path Labs has strong.

DCB Bank Ltd. 1 P a g e

Thermax. Institutional Equities. 3QFY18 Result Update. Healthy Execution, But Margins Disappoint SELL

Punjab National Bank

FLEXING ITS WEIGHT, INVESTING IN THE FUTURE

EBITDA 6,223 6,511 (4.4) 5, EBITDA

KPIT Cummins Infosystems Ltd

Mangalam Cement. Institutional Equities. 3QFY18 Result Update. Higher Operating costs Hurt Performance BUY

Institutional Equities

Voltas. Institutional Equities. 1QFY19 Result Update. EMPS Shines, UCP Proves Its Mettle Again ACCUMULATE

Pennar Industries Ltd.

Bajaj Electricals Ltd.

Eicher Motors. Institutional Equities. Management Meet Update BUY. Reuters: EICH.NS; Bloomberg: EIM IN

26 October 2018 Reuters: MRTI.BO; Bloomberg: MSIL IN

Institutional Equities

Robust results, TLT margins improved profitability.

LIC Housing Finance Ltd

EBITDA 2,503 2,904 (13.8) 2,722 (8.0) EBITDA

Institutional Equities

Institutional Equities

Hindustan Unilever. Institutional Equities. 4QFY18 Result Update

Institutional Equities

Karnataka Bank. Institutional Equities. 4QFY18 Result Update. Plucky Bank And Low Hanging Fruit BUY. 17 May Reuters: KBNK.NS; Bloomberg: KBL IN

HOLD. Deleveraging story playing out RAMCO CEMENTS. Target Price: Rs 503. Q4 performance

CMP* (Rs) 208 Upside/ (Downside) (%) 18. Market Cap. (Rs bn) Free Float (%) 65.6 Shares O/S (mn) 630

Hindustan Unilever. Institutional Equities. 1QFY19 Result Update

ACC. Institutional Equities. Event Update. Capacity Expansion To Consolidate Presence In Central India ACCUMULATE

Manappuram Finance. Institutional Equities. 3QFY18 Result Update. The Glitter Is Back In Gold Loans BUY. 9 February 2018

PNB Housing Finance. Institutional Equities. 4QFY18 Result Update BUY. Continued Display of Embedded Scalability. 4 May 2018

Recommendation HOLD Dismal performance drags margins Appreciating Japanese Yen, drop in volumes and increase in. Rs. 1,126.

Garware Wall Ropes ACCUMULATE. Performance Highlights CMP. `550 Target Price `618. 2QFY2017 Result Update Textile. Investment Period 12 months

Swaraj Engines. Institutional Equities. 2QFY18 Result Update ACCUMULATE

Dabur India. Institutional Equities. 4QFY18 Result Update. Growth Volatility Is Still Fairly High ACCUMULATE

EBITDA 1,548 1,814 (14.7) 1,561 (0.8) EBITDA

BUY. White cement steals the show JK CEMENT. Target Price: Rs 1,220. Other highlights

Techno Electric & Engineering Limited

BUY. Efforts on cost cutting paying off RAMCO CEMENTS. Target Price: Rs 435. Key highlights. Key drivers FY15 FY16E FY17E

Mold-Tek Packaging Limited

Dabur India. Institutional Equities. 1QFY19 Result Update

Sequent Scientific. Institutional Equities. 1QFY19 Result Update BUY

TVS Motor Company. Institutional Equities. 3QFY19 Result Update SELL

Key highlights of the quarter

CMP (Rs) 775 Upside/ (Downside) (%) (1.4) Market Cap. (Rs bn) 11.4 Free Float (%) 35.0 Shares O/S (mn) 14.7

2,09,057 1,85,859 2,17, (4.1) NIM

Bharat Financial Inclusion

HOLD. Coal India Ltd Coal RETAIL EQUITY RESEARCH. Uncertainty remains. GEOJIT BNP PARIBAS Research

The Ramco Cements. Institutional Equities. Event Update BUY

Amber Enterprises India Ltd

ITC ACCUMULATE. Performance Highlights CMP. `257 Target Price `284. 3QFY2017 Result Update FMCG. Investment Period 12 Months

Inox Wind BUY. Performance Highlights. CMP Target Price `242 `286. 4QFY2016 Result Update Capital Goods. 3 year price chart

CMP* (Rs) 242 Upside/ (Downside) (%) 2. Market Cap. (Rs bn) 157 Free Float (%) 65.6 Shares O/S (mn) 630

IFB Industries. Institutional Equities. 3QFY18 Result Update. Healthy Revenues, Strong Gross Margin; Retain Buy BUY.

Amara Raja Batteries BUY. Performance Highlights. CMP `1,010 Target Price `1,167. 2QFY2017 Result Update Auto Ancillary. 3-year price chart

Bharat Forge. Result Update. Q4FY13 Result Highlights. Valuation. No Respite in Sight May 29, Institutional Research 1

Kalpataru Power. Rating: Target price: EPS: Rating CMP. Target BUY. Rs Rs.256

Change EPS. (Rs) FY

Dalmia Bharat Enterprises

Key highlights for the year

Performance beat on all fronts

Key estimate revision. Financial summary. Year FY14 391,088 45,198 34, FY15E 354,262 35,426 23,

Larsen & Toubro Ltd.

Dalmia Bharat Enterprises

9,500 7,914 8, NIM

CMP* (Rs) 263 Upside/ (Downside) (%) 7.3. Market Cap. (Rs bn) 635 Free Float (%) 59 Shares O/S (mn) 2,417

InterGlobe Aviation Ltd Plastic Products. BUY Rating as per Midcap 12months investment period RETAIL EQUITY RESEARCH

EBITDA 1,585 1,917 (17.3) 1,673 (5.2) EBITDA

CMP* (Rs) 336 Upside/ (Downside) (%) 21 Bloomberg Ticker. MOIL IN Market Cap. (Rs bn) 45 Free Float (%) 24 Shares O/S (mn) 133

Quarterly Result Analysis

Titan Company BUY. Back to Value Zone Validate Rating Upgrade. Institutional Equity Research. November 05, Target Price Rs428.

Grindwell Norton Ltd

FINOLEX CABLES Ltd Electrical Equipments. Buy RETAIL EQUITY RESEARCH

Adani Ports & SEZ Rating: Target price: EPS:

Institutional Equities

Apollo Hospitals Enterprise Ltd.

Transcription:

Aug-17 Sep-17 Oct-17 Nov-17 Dec-17 Jan-18 Feb-18 Mar-18 Apr-18 May-18 Jun-18 Jul-18 Aug-18 2904 Recommendation CMP Target Price BUY Rs. 312 Rs. 443 Better times ahead! reported a good set of numbers in Q1FY19. Sales for the quarter increase by 17.4% YoY to Rs 1904.9 Cr. During the quarter, the company witnessed a strong overall sales volume growth of 14.9% YoY, with packaging Sector Plastic business volumes growing 11% and film volumes growing at 15.9% YoY. The management has maintained its guidance for double digit overall sales volumes Stock Details growth in FY19 with improved margins of 15%, given the stability in crude prices. BSE Code 500148 EBITDA margins saw a dip from 14.3% in Q1FY18 to 13% in Q1FY19 and remained NSE Code Bloomberg Code UFLEX UFLX IN flat on a QoQ basis. The negative impact on EBITDA margins was primarily because of a sharp spike in crude oil prices squeezing the packaging business margins. PAT in Q1FY19 was at Rs. 94.1Cr with PAT Margins higher by 1% QoQ. Market Cap (Rs cr) Rs. 2247 Free Float (%) 56.0% 52- wk HI/Lo (Rs) 507/265 Avg. volume BSE + NSE (Qrly) 176560 Face Value Rs. 10 Dividend (FY 18) 20% Shares o/s (Cr) 7.2 Relative Performance 1Mth 3Mth 1Yr Uflex 21.6% 2.2% -26.4% Sensex 3.7% 6.4% 18.5% 600 400 200 Shareholding Pattern Jun 18 Promoters Holding 44.0% Institutional (Incl. FII) 11.1% Corporate Bodies 11.0% Public & others 33.9% Runjhun Jain (+91 22 6273 8177) Sr. Research Analyst runjhun.jain@nirmalbang.com Dnyanada K. Vaidya (+91 22 6273 8186) Research Associate dnyanada.vaidya@nirmalbang.com Key Highlights Aseptic Packaging: The company is seeing good traction and currently serves 20 customers vs. 12 in Q4FY18. The plant is currently running at 20-25% capacity utilization, and the management is taking efforts to rope in large clients. Though the company does not see any pricing pressure, however there could be a lag of 1-2 quarters, to achieve targeted revenue of Rs. 350Cr. The company witnessed a pressure on the standalone packaging business margin due to a sharp spike in crude prices, which it could not pass on to the customers. However, it is likely to get normalized in Q2 and with the crude prices stabilizing, there would be an improvement in margins. The BOPET industry continuous to see an improvement with respect to both demand and margins. The company realized margins of Rs. 50/kg in BOPET films vs. Rs. 32/kg in Q1FY18 and believes to add another Rs. 3-4/kg to the margins going ahead. Higher demand has resulted in a healthy order book for the company. The BOPP industry is facing margin pressures and constitutes a small portion of Uflex s product portfolio. The management believes this will not significantly affect its margins going ahead. The company had taken up expansion of the holographic line in Jammu incurring a capex of ~Rs. 150 Cr, which is likely be completed by Q2FY19. The management expects the line to add ~Rs. 200 Cr to the top line with a margin of 25-30%. Valuation & Recommendation We expect Uflex s revenues to grow at 11.5% CAGR from FY18-20E and EBITDA to grow at 16.6% during the same period. PAT is expected to grow at 30.5% CAGR during the same period. ROE is expected to improve from 7.8% in FY18 to 11.0% in FY20E and ROCE shall improve from 8.7% in FY18 to 11.6% in FY20E. We have valued the company on EV/EBITDA basis, as we believe that packaging business deserves a higher multiple than the commoditized film business. We have valued Packaging business incl. Aseptic at 6x EV/EBITDA on FY19E EBITDA and the films business at 4.5x on FY19E earnings and arrived at a target of INR 443, which implies 42% upside from current levels. We maintain BUY rating on the stock. Consolidated Sales (Cr) Growth EBITDA (Cr) Margin PAT Margin EPS (Rs) P/E RoE FY17A 6156.7 2.0% 874.3 14.2% 348.5 5.7% 48.3 6.5 9.6% FY18A 6786.5 10.2% 879.4 13.0% 310.5 4.6% 43.0 7.3 7.8% FY19E 7417.1 9.3% 993.9 13.4% 395.5 5.3% 54.8 5.7 9.1% FY20E 8341.0 12.5% 1166.9 14.0% 533.4 6.4% 73.9 4.2 11.0% 1

Quarterly Result The company continues to see a healthy volume growth during the quarter, with Film business registering a stellar growth of 15.9% YoY and the packaging business growing 11% YoY during the quarter. The company expects the growth momentum to continue for the rest of FY19 and have maintained the earlier guidance of overall volume growth of 10% (Packaging volume growth >12% and films business volume growth 6-7%) Revenues for Q1FY19 stood at Rs.1904.9 Cr vs. Rs. 1622.6 Cr during Q1FY18, growing at 17.4% YoY. EBITDA Margins during Q1FY19 were subdued on the back of increase in raw material prices and a sharp increase in crude oil prices. EBITDA margins saw a dip from 14.3% in Q1FY18 to 13.0% in Q1FY19, but improved from 12.3% in Q4FY18. The packaging business faced headwinds due to macro-economic factors, such as a sharp rise in crude oil prices by 17% during the quarter. The pressure on the margins is owing to the lag of 1-2 months in passing on the prices to the customer. The management expects the prices to stabilize in the coming quarter and thus improve margins. Interest is expected to decline, as the company is likely to reduce its net debt by Rs. 150-200 Cr till the end of FY19. Fig 1. - Packaging Business Volume Growth (YoY) Fig 2. - Films Business Volumes Growth (YoY) 2

Financials (Consolidated) Profit & Loss FY17A FY18A FY19E FY20E Balance Sheet FY17A FY18A FY19E FY20E Net Sales 6156.7 6786.5 7417.1 8341.0 Property and CWIP 3858.4 3917.8 3880.5 3960.6 % change 2.0% 10.2% 9.3% 12.5% Total Investments 34.1 43.7 43.7 43.7 EBITDA 874.3 879.4 993.9 1166.9 Oth Non CA 210.1 196.4 308.8 309.8 EBITDA margin 14.2% 13.0% 13.4% 14.0% Inventories 678.6 796.8 927.1 1042.6 Depn & Amort 317.5 351.6 362.1 385.0 Debtors 1659.0 1939.0 2183.9 2502.3 Operating income 556.8 527.8 631.7 781.9 Cash & Bank 296.3 315.5 402.5 407.1 Interest 186.8 197.1 182.9 168.9 Current Tax Assets 0.0 0.0 0.0 0.0 Other Income 20.5 20.0 22.0 22.0 Other Current Assets 368.7 435.5 431.7 433.7 PBT 390.4 350.7 470.9 635.0 Total Assets 7148.6 7688.2 8221.7 8743.2 Tax 43.8 41.7 75.3 101.6 Total Equity 3628.8 3974.7 4354.2 4862.3 MI & EO -1.8-1.5 0.0 0.0 Non Controlling Int. 15.2 4.9 4.9 4.9 PAT 348.5 310.5 395.5 533.4 Total Borrowings 2102.1 2079.4 2009.5 1856.5 PAT margin (%) 5.7% 4.6% 5.3% 6.4% Total Provisions 30.8 32.2 32.2 32.2 Sh o/s - Diluted 7.2 7.2 7.2 7.2 Other Non CL 129.8 132.6 132.6 132.6 Adj EPS 48.3 43.0 54.8 73.9 Trade Payables 957.3 1196.4 1318.6 1482.8 Cash EPS 92.2 91.7 104.9 127.2 Current Tax Liabilitie 35.4 18.5 18.5 18.5 Qtrly-Consol Sept.17 Dec.17 Mar.18 Jun.18 Other CL 244.4 243.8 345.7 347.7 Revenue 1593.3 1674.4 1811.6 1904.9 Total Eq. & Liabilities 7148.6 7688.2 8221.7 8743.2 EBITDA 229.7 194.4 223.5 247.7 Cash Flow FY17A FY18A FY19E FY20E Dep & Amorz 84.5 91.2 92.6 92.1 EBITDA 874.3 879.4 993.9 1166.9 Op Income 145.2 103.2 130.9 155.6 Change in WC 119.1-225.3-259.8-270.6 Interest 43.8 56.9 51.3 53.4 Tax -43.8-41.7-75.3-101.6 Other Inc. 5.8 5.3 5.0 6.1 CF from Operation 949.7 612.4 658.7 794.7 PBT 107.3 51.6 84.6 108.3 Capex -627.3-275.3-324.8-465.0 Tax 13.6 0.0 13.9 15.3 Oth Inc & Investmen 21.9 10.3 22.0 22.0 EO -0.6-0.4-0.5-1.1 CF from Investing -605.3-265.0-302.8-443.0 PAT 94.3 52.0 71.1 94.1 Financing EPS (Rs.) 13.1 7.2 9.9 13.0 Diviend Paid -27.8-30.4-14.4-25.3 Performance Ratio FY17A FY18A FY19E FY20E Share Capital 0.0 0.0 0.0 0.0 EBITDA margin(%) 14.2% 13.0% 13.4% 14.0% Loans -37.4-22.7-69.9-153.0 EBIT margin (%) 9.0% 7.8% 8.5% 9.4% Interest -186.8-197.1-182.9-168.9 PAT margin (%) 5.7% 4.6% 5.3% 6.4% Others -184.0-78.0-1.7 0.2 ROE (%) 9.6% 7.8% 9.1% 11.0% CF from Financing -435.9-328.2-268.9-347.0 ROCE (%) 9.7% 8.7% 9.9% 11.6% Net Chg. in Cash -91.6 19.2 86.9 4.7 PAT growth (%) 11.0% -10.9% 27.4% 34.9% Cash at beginning 387.9 296.3 315.5 402.5 Debt/Equity (x) 0.6 0.5 0.5 0.4 Cash at end 296.3 315.5 402.5 407.1 Valuation Ratio FY17A FY18A FY19E FY20E Per Share Data FY17A FY18A FY19E FY20E PE (x) 6.5 7.3 5.7 4.2 Adj EPS 48.3 43.0 54.8 73.9 Price/BV (x) 0.6 0.6 0.5 0.5 BV per share 502.5 550.4 603.0 673.3 EV / Sales 0.7 0.6 0.5 0.4 Cash per share 41.0 43.7 55.7 56.4 EV / EBITDA 4.6 4.6 3.9 3.2 Dividend per share 3.9 4.2 2.0 3.5 3

Disclosure: This Report is published by Nirmal Bang Securities Private Limited (hereinafter referred to as NBSPL ) for private circulation. NBSPL is a registered Research Analyst under SEBI (Research Analyst) Regulations, 2014 having Registration no. INH000001766. NBSPL is also a registered Stock Broker with National Stock Exchange of India Limited and BSE Limited in cash and derivatives segments. It is also a registered Portfolio Manager having registration no as INP000002981. NBSPL has other business divisions with independent research teams separated by Chinese walls, and therefore may, at times, have different or contrary views on stocks and markets. NBSPL or its associates have not been debarred / suspended by SEBI or any other regulatory authority for accessing / dealing in securities Market. NBSPL, its associates or analyst or his relatives do not hold any financial interest in the subject company. NBSPL or its associates or Analyst do not have any conflict or material conflict of interest at the time of publication of the research report with the subject company. NBSPL or its associates or Analyst or his relatives hold / do not hold beneficial ownership of 1% or more in the subject company at the end of the month immediately preceding the date of publication of this research report. NBSPL or its associates / analyst has not received any compensation / managed or co-managed public offering of securities of the company covered by Analyst during the past twelve months. NBSPL or its associates have not received any compensation or other benefits from the company covered by Analyst or third party in connection with the research report. Analyst has not served as an officer, director or employee of Subject Company and NBSPL / analyst has not been engaged in market making activity of the subject company. Analyst Certification: I/We, Runjhun Jain, Research Analyst and Dnyanada Vaidya, Research Associate authors of this report, hereby certify that the views expressed in this research report accurately reflects my/our personal views about the subject securities, issuers, products, sectors or industries. It is also certified that no part of the compensation of the analyst(s) was, is, or will be directly or indirectly related to the inclusion of specific recommendations or views in this research. The analyst(s) principally responsible for the preparation of this research report and has taken reasonable care to achieve and maintain independence and objectivity in making any recommendations. 4

Disclaimer: This report is for the personal information of the authorized recipient and does not construe to be any investment, legal or taxation advice to you. NBSPL is not soliciting any action based upon it. Nothing in this research shall be construed as a solicitation to buy or sell any security or product, or to engage in or refrain from engaging in any such transaction. In preparing this research, we did not take into account the investment objectives, financial situation and particular needs of the reader. This research has been prepared for the general use of the clients of NBSPL and must not be copied, either in whole or in part, or distributed or redistributed to any other person in any form. If you are not the intended recipient you must not use or disclose the information in this research in any way. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. NBSPL will not treat recipients as customers by virtue of their receiving this report. This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject NBSPL & its group companies to registration or licensing requirements within such jurisdictions. The report is based on the information obtained from sources believed to be reliable, but we do not make any representation or warranty that it is accurate, complete or up-to-date and it should not be relied upon as such. We accept no obligation to correct or update the information or opinions in it. NBSPL or any of its affiliates or employees shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. NBSPL or any of its affiliates or employees do not provide, at any time, any express or implied warranty of any kind, regarding any matter pertaining to this report, including without limitation the implied warranties of merchantability, fitness for a particular purpose, and non-infringement. The recipients of this report should rely on their own investigations. This information is subject to change without any prior notice. NBSPL reserves its absolute discretion and right to make or refrain from making modifications and alterations to this statement from time to time. Nevertheless, NBSPL is committed to providing independent and transparent recommendations to its clients, and would be happy to provide information in response to specific client queries. Before making an investment decision on the basis of this research, the reader needs to consider, with or without the assistance of an adviser, whether the advice is appropriate in light of their particular investment needs, objectives and financial circumstances. There are risks involved in securities trading. The price of securities can and does fluctuate, and an individual security may even become valueless. International investors are reminded of the additional risks inherent in international investments, such as currency fluctuations and international stock market or economic conditions, which may adversely affect the value of the investment. Opinions expressed are subject to change without any notice. Neither the company nor the director or the employees of NBSPL accept any liability whatsoever for any direct, indirect, consequential or other loss arising from any use of this research and/or further communication in relation to this research. Here it may be noted that neither NBSPL, nor its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profit that may arise from or in connection with the use of the information contained in this report. Copyright of this document vests exclusively with NBSPL. Our reports are also available on our website www.nirmalbang.com Nirmal Bang Research (Division of Nirmal Bang Securities Pvt. Ltd.) B-2, 301/302, Marathon Innova, Opp. Peninsula Corporate Park Off. Ganpatrao Kadam Marg Lower Parel (W), Mumbai-400013 Board No. : 91 22 6723 8000/8001 Fax. : 022 6723 8010 5